Genomic Assays for Chemotherapy Decisions in ER-Positive/HER2-Negative Breast Cancer

Precision Medicine in Oncology Podcast Series: Ep12. Biomarkers for the treatment of breast cancerПодробнее

Advocate Chat: Genomic Profiling in Breast Cancer for Treatment Decision MakingПодробнее

HER2-Negative Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Ma...Подробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Genomic Profiling in early stage breast cancer & Role of Mammaprint & Blueprint testing | OncquestПодробнее

Pursue 10 D (Uploaded): Molecular Profiling of Breast Carcinoma & Rare Subtypes of Breast CarcinomaПодробнее

MammaPrint BluePrint Mindact Follow up data 8 years and Molecular SubtypeПодробнее

How to Treat Estrogen Receptor-Low Breast Cancer: All You Need to KnowПодробнее

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer Guideline UpdateПодробнее

Dr. Charles Perou | Distinguished Lectureship in Breast Cancer Research | SABCS 2022Подробнее

Will I need Chemotherapy for My Breast Cancer?Подробнее

Adjuvant/Neoadjuvant Therapy for Breast Cancer: Updates and Molecular Predictors of BenefitПодробнее

Hormonal Therapy for Breast Cancer: We Teach YouПодробнее

Molecular Testing in Breast Cancer: Will it Become Standard Practice? - Kimberly Allison, MDПодробнее

Genomic Assays Impact Treatment Decisions in Patients With ER+ Breast CancerПодробнее

Molecular Testing in Breast Cancer: Will it Become Standard Practice?Подробнее

Genomic Testing in Breast Cancer: What You Must KnowПодробнее

Genomic Assays Impact Treatment Decisions in Patients With ER+ Breast CancerПодробнее

Utilizing Genomic Assays for Decision Making in Early Stage Breast CancerПодробнее